Compounds > irofulven
Page last updated: 2024-09-04

irofulven and Prostatic Neoplasms

irofulven has been researched along with Prostatic Neoplasms in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's6 (85.71)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
MacDonald, JR; Van Laar, ES; Waters, SJ; Weitman, S1
Herman, TS; Kosakowska-Cholody, T; Leal, BZ; Liang, H; Michejda, CJ; Salinas, RA; Waters, SJ; Woynarowska, BA; Woynarowski, JM1
Arsenau, J; Berman, B; MacDonald, JR; Richards, D; Senzer, N; Smith, S1
Bossi, A; Chauchereau, A; de Crevoisier, R; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Thuret, R1
McMorris, TC1
Herman, TS; MacDonald, JR; Roberts, K; Woynarowska, BA; Woynarowski, JM1
Bushong, P; Muñoz, RM; Waters, SJ; Woynarowska BAHigdon, AL1

Reviews

1 review(s) available for irofulven and Prostatic Neoplasms

ArticleYear
Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug.
    Bioorganic & medicinal chemistry, 1999, Volume: 7, Issue:5

    Topics: Animals; Antibiotics, Antineoplastic; Clinical Trials as Topic; Humans; Male; Mice; Models, Chemical; Prostatic Neoplasms; Rats; Sesquiterpenes; Technology, Pharmaceutical; Tumor Cells, Cultured

1999

Trials

1 trial(s) available for irofulven and Prostatic Neoplasms

ArticleYear
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial.
    American journal of clinical oncology, 2005, Volume: 28, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Survival Analysis

2005

Other Studies

5 other study(ies) available for irofulven and Prostatic Neoplasms

ArticleYear
Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
    The Prostate, 2004, Apr-01, Volume: 59, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Nude; Mitoxantrone; Prostatic Neoplasms; Sesquiterpenes; Taxoids; Xenograft Model Antitumor Assays

2004
Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:11

    Topics: Apoptosis; bcl-2-Associated X Protein; Bridged Bicyclo Compounds; Caspases; Cell Line, Tumor; Cell Proliferation; Cytochromes c; DNA Fragmentation; Enzyme Inhibitors; Humans; Male; Mitochondria; Molecular Structure; Prostatic Neoplasms; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Sesquiterpenes; Signal Transduction

2004
The postchemotherapy PSA surge syndrome.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Syndrome; Taxoids; Treatment Outcome

2008
Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells.
    Radiation research, 2000, Volume: 154, Issue:4

    Topics: Adenocarcinoma; Androgens; Antineoplastic Agents, Alkylating; Apoptosis; Combined Modality Therapy; DNA Damage; Gamma Rays; Humans; Intestinal Mucosa; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Sesquiterpenes; Tumor Cells, Cultured; Tumor Stem Cell Assay

2000
Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven.
    Investigational new drugs, 2001, Volume: 19, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Cell Division; DNA Primers; Gene Expression Regulation, Neoplastic; Humans; Immunoradiometric Assay; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sesquiterpenes; Tumor Cells, Cultured

2001